A Brief History of India's Pharmaceutical Regulatory Framework

India's modern pharmaceutical regulatory framework has its roots in the Drugs and Cosmetics Act of 1940, enacted during the colonial period to regulate the import, manufacture, distribution, and sale of drugs across the country. The Act, along with its accompanying Rules of 1945, established the basic architecture still recognizable in Indian pharmaceutical law today: licensing requirements for manufacturers, standards for drug quality and labeling, and enforcement mechanisms carried out jointly by central and state authorities.

The decades following independence saw India build out the institutions needed to administer this framework at national scale. The Central Drugs Standard Control Organization, commonly known as the CDSCO, developed into the country's central drug regulatory authority, responsible for approving new drugs, setting standards for drugs and cosmetics, and coordinating with state drug licensing authorities that handle manufacturing licenses and local enforcement within their jurisdictions. This dual central-and-state structure reflects the scale of the country's pharmaceutical industry — thousands of licensed manufacturing units spread across every region — and required decades of institutional development to administer effectively.

A significant turning point came with the shift in patent law discussed elsewhere on this blog: India's move from a process-patent to a product-patent regime in 2005, made in order to comply with the World Trade Organization's TRIPS agreement. This change realigned Indian pharmaceutical law with the international patent standards followed by most major economies, and it coincided with an increased regulatory focus on aligning Indian manufacturing quality standards with those expected by international markets, since Indian companies were now competing more directly for global export opportunities on the same patent terms as manufacturers everywhere else.

Since then, India has continued to strengthen its pharmacovigilance systems for monitoring drug safety after approval, its clinical trial regulations, and its manufacturing inspection processes, often in active dialogue with international regulatory counterparts including the US FDA and the World Health Organization. Indian regulatory authorities today participate in international harmonization efforts aimed at aligning technical requirements across countries, reducing duplicative testing, and raising the baseline expectation for manufacturing quality across the global generics industry.

Understanding this history matters because it shows that India's current standing as a major pharmaceutical manufacturing hub was not achieved through weak regulation, but through more than a century of evolving regulatory infrastructure — infrastructure that has been repeatedly adapted to meet rising domestic and international expectations. The framework governing a facility today is the product of that long institutional history, not an absence of one.